Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 7/20 | 0.69 |
| ▸ | LMNA | P02545 | 7/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.69 |
| ▸ | SERPINA6 | P08185 | 6/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.69 |
| ▸ | BLM | P54132 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.69 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | PGR | P06401 | 3/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.65 |
| ▸ | HTR2B | P41595 | 2/20 | 0.65 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 5/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10867342 | 1.00 | SHBG (0.69) | SHBGLMNASMN1; SMN2SERPINA6NR3C1 | |
| SCHEMBL10867348 | 1.00 | SHBG (0.69) | SHBGLMNASMN1; SMN2SERPINA6NR3C1 | |
| SCHEMBL9347593 | 0.86 | SHBG (0.70) | SHBGLMNASMN1; SMN2SERPINA6NR3C1 | |
| SCHEMBL10444770 | 0.85 | LMNA (0.49) | SHBGLMNASMN1; SMN2SERPINA6NR3C1 | |
| SCHEMBL15079258 | 0.85 | LMNA (0.49) | SHBGLMNASMN1; SMN2SERPINA6NR3C1 | |
| SCHEMBL10444897 | 0.85 | LMNA (0.49) | SHBGLMNASMN1; SMN2SERPINA6NR3C1 | |
| SCHEMBL15079253 | 0.85 | LMNA (0.49) | SHBGLMNASMN1; SMN2SERPINA6NR3C1 | |
| Haloprogesterone SCHEMBL5886134 | 0.84 | NR3C1 (0.53) | SHBGLMNASMN1; SMN2SERPINA6NR3C1 | |
| SCHEMBL571579 | 0.83 | LMNA (0.65) | SHBGLMNASMN1; SMN2SERPINA6NR3C1 | |
| SCHEMBL571580 | 0.82 | LMNA (0.47) | SHBGLMNASMN1; SMN2SERPINA6NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101883556-B | Transdermal delivery system for hormones and steroids | ACRUX DDS PTY LTD | 2013-05-29 | — | — | CN | claimed |
| US-8110565-B2 | Of the ACE inhibitor ramipril; controlling the melting point by mixing with the free acid with the ramipril ethyl or methyl ester prodrug and a pressure sensitive adhesive carrier; improved pharmacokinetics; sustained release | NOVEN PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | claimed |
| EP-1406633-B1 | ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS | NOVEN PHARMA (US) | 2011-10-05 | — | — | EP | claimed |
| US-20110195114-A1 | TRANSDERMAL DELIVERY SYSTEMS FOR ACTIVE AGENTS | ANTARES PHARMA, IPL, AG | 2011-08-11 | — | — | US | claimed |
| CN-100544725-C | Androgen pharmaceutical composition and pharmaceutical application thereof | UNIMED PHARMACEUTICALS INC BES (US) | 2009-09-30 | — | — | CN | claimed |
| US-7456159-B2 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | claimed |
| US-20080167280-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2008-07-10 | — | — | US | claimed |
| CN-100391462-C | Enhanced drug delivery in transdermal systems | NOVEN PHARMA (US) | 2008-06-04 | — | — | CN | claimed |
| CN-1997357-A | Use and formulation of active agents for transdermal or transmucosal application | ANTARES PHARMA IPL AG (CH) | 2007-07-11 | — | — | CN | claimed |
| EP-1406633-A4 | ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS | NOVEN PHARMA (US) | 2006-08-16 | — | — | EP | claimed |
| US-20030232073-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | claimed |
| US-20030152615-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | claimed |
| US-20030152613-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | claimed |
| US-20030152614-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | claimed |
| WO-2002102390-A1 | ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS | NOVEN PHARMACEUTICALS, INC. (US) | 2002-12-27 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-4588529-A | Mercury removal process | THE UPJOHN COMPANY (US) | 1986-05-13 | — | — | US | claimed |
| US-4567001-A | 16-Methylene-17α-hydroxy-progesterones | THE UPJOHN COMPANY (US) | 1986-01-28 | — | — | US | claimed |
| EP-0104054-A2 | 16-methylene-steroids and their preparation | THE UPJOHN COMPANY (US) | 1984-03-28 | — | — | EP | claimed |